Bryce Point Capital, LLC Celldex Therapeutics, Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 23,790 shares of CLDX stock, worth $529,565. This represents 0.17% of its overall portfolio holdings.
Number of Shares
23,790Holding current value
$529,565% of portfolio
0.17%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
194Shares Held
64.9MCall Options Held
1.65MPut Options Held
973K-
Wellington Management Group LLP Boston, MA8.98MShares$200 Million0.04% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$104 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$86.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$77 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$74.2 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.04B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...